Organization | University of Queensland

University of Queensland Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Brisbane Australia (1909)

Organization Overview

First Clinical Trial

1998

NCT00097669

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

ANZIC-Research Centre; Australian Defence Force, University of Queensland, | Brisbane Public Hospital | Brisbane South Medical Centre | Children's Health Queensland | Dermatology Department, Brisbane Public Hospital | Greenslopes Private Hospital | Isopogen | Lady Cilento Children's Hospital, Brisbane | Nambour General Hospital, Queensland | QIMR Berghofer Medical Research Institute | Queensland Centre for Gynaecological Cancer | Queensland Children's Medical Research Institute | Queensland Children's Medical Research Unit, Herston, AUS | Queensland Institute for Medical Research | Queensland Institute of Medical Research | Redcliffe Hospital, Brisbane, Qld., Australia | Royal Brisbane and Women's Hospital | Royal Brisbane and Womens Hospital | Royal Brisbane and Womens Hospital, Brisbane, Australia | Royal Brisbane & Women's Hospital, QLD, Australia | Royal Brisbane & Women's Hpsoital | The Prince Charles Hospital | The Prince Charles Hospital, Centre for Biodiscovery and Molecular Development of Therapeutics | The Univeristy of Queensland | The University of Queensland | The University of Queensland Centre for Clinical Research | Univeristy of Queensland | University of Queeensland, University of South Australia | University of Queensland, Queensland, Australia | University of Queensland, Queensland Health | University of Queensland & The Prince Charles Hospital | UQCCR

Active Ingredients

Drugs in Phase 4 Trials (23)

albendazole (Albenza) (1 trial)

benzylpenicillin (1 trial)

cefazolin (ancef) (2 trials)

clavulanate (Augmentin) (1 trial)

clindamycin (cleocin) (1 trial)

enoxaparin (lovenox) (1 trial)

eucalyptus oil (2 trials)

fish oil (Omegavan) (1 trial)

flucloxacillin (1 trial)

heparin (liquaemin) (1 trial)

kavalactones (1 trial)

lavender oil (1 trial)

mebendazole (vermox) (1 trial)

meropenem (merrem) (3 trials)

penicillin (1 trial)

piperacillin (pipracil) (3 trials)

posaconazole (noxafil) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

tacrolimus (prograf) (1 trial)

tazobactam (Zosyn) (3 trials)

tirofiban (aggrastat) (1 trial)

ti tree oil (1 trial)

vancomycin (Vancocin) (1 trial)

Drugs in Phase 3 Trials (36)

amikacin (Amikin) (1 trial)

azithromycin (zithromax) (2 trials)

bedaquiline (sirturo) (1 trial)

cefoxitin (mefoxin) (1 trial)

ceftolozane (Zerbaxa) (1 trial)

ciprofloxacin (cipro) (1 trial)

clarithromycin (biaxin) (1 trial)

clofazimine (lamprene) (1 trial)

clonidine (catapres) (1 trial)

cotrimoxazole (1 trial)

dexmedetomidine (precedex) (1 trial)

dipeptiven (1 trial)

doxycycline (vibramycin) (1 trial)

ethambutol (myambutol) (1 trial)

human fecal microbiota (Reybota) (2 trials)

imipenem (primaxin) (1 trial)

immune globulin (human) (1 trial)

insulin detemir (Levemir) (1 trial)

ismigen (1 trial)

leptospermum petersonii leaf oil (1 trial)

linezolid (zyvox) (1 trial)

melatonin (1 trial)

metformin (glucophage) (1 trial)

moxifloxacin (avelox) (1 trial)

palmitoylethanolamide (1 trial)

pentastarch (Pentaspan) (1 trial)

piperonyl butoxide (Rid Mousse) (1 trial)

platelets (1 trial)

propofol (diprivan) (1 trial)

pyrethrins (rid mousse) (1 trial)

rifabutin (mycobutin) (1 trial)

sodium chloride (3 trials)

sulfamethoxazole (gantanol) (1 trial)

tigecycline (tygacil) (1 trial)

trimethoprim (1 trial)

Drugs in Phase 2 Trials (32)

acetaminophen (tylenol) (1 trial)

albuterol (proventil) (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

artefenomel (4 trials)

atovaquone (mepron) (1 trial)

budesonide (rhinocort) (1 trial)

carboplatin (paraplatin) (1 trial)

cefiderocol (Fetroja) (1 trial)

dabrafenib (tafinlar) (1 trial)

danazol (danocrine) (1 trial)

dsm265 (2 trials)

grn163l (1 trial)

hypericum perforatum (1 trial)

ipratropium (atrovent) (1 trial)

levetiracetam (keppra) (1 trial)

mannitol (1 trial)

mmv390048 (2 trials)

muc1 dendritic cell vaccine (1 trial)

necator americanus (2 trials)

norgestrel (Ovral) (1 trial)

paclitaxel (taxol) (1 trial)

piperaquinoline (4 trials)

primaquine (1 trial)

proguanil (1 trial)

pyrimethamine (daraprim) (1 trial)

sitagliptin (januvia) (1 trial)

sulfadoxine (1 trial)

trametinib (mekinist) (1 trial)

triheptanoin (1 trial)

trimetazidine (1 trial)

Drugs in Phase 1 Trials (20)

allogeneic plx-pad cells (1 trial)

autologous ade1- latent membrane protein ctls (1 trial)

cva21 (1 trial)

domperidone (1 trial)

donor stem cell (1 trial)

fludrocortisone (florinef) (1 trial)

ingenol mebutate (picato) (1 trial)

lutein (1 trial)

nicotine (nicorette) (1 trial)

Phage Cocktail-SPK (1 trial)

pilocarpine (ocusert) (1 trial)

presatovir (1 trial)

sars-cov-2 sclamp vaccine (1 trial)

sibling umbilical cord blood (1 trial)

(+)-sj000557733 (1 trial)

streptococcus pyogenes (1 trial)

tolterodine (detrol) (1 trial)

Drugs in Other Trials (14)

crateva nurvala stem bark (1 trial)

equisetum arvense sp (1 trial)

ethanol (1 trial)

fansidar (1 trial)

folic acid (1 trial)

hydroxocobalamin (cyanokit) (1 trial)

inactivated influenza vaccine (1 trial)

lidocaine (xylocaine) (1 trial)

lindera aggregata root (1 trial)

malarone (1 trial)

pyridoxine (1 trial)

rifaximin (xifaxan) (1 trial)

selenium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Coronary Syndrome (Phase 4)

Adenocarcinoma (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 1)

Anxiety Disorders (Phase 4)

Ataxia (Phase 2)

Ataxia Telangiectasia (Phase 2)

Atrophy (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Bacteremia (Phase 3)

Bacterial Infections (Phase 1)

Behavior, Addictive (Phase 1)

Blood Loss, Surgical (Phase 3)

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Bronchiectasis (Phase 3)

Carcinoma, Endometrioid (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Celiac Disease (Phase 2)

Cerebellar Ataxia (Phase 2)

Cerebral Palsy (Phase 1)

Cognitive Dysfunction (Phase 2)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Communicable Diseases (Phase 4)

Coxsackievirus Infections (Phase 1)

Critical Illness (Phase 3)

Crohn Disease (Phase 1)

Cystic Fibrosis (Phase 3)

Delayed Graft Function (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 4)

Dyskeratosis Congenita (Phase 2)

Endometrial Hyperplasia (Phase 2)

Familial Primary Pulmonary Hypertension (Phase 1)

Fibrosis (Phase 3)

Gram-Positive Bacterial Infections (Phase 1)

Hemolysis (Phase 1)

Hemorrhage (Phase 3)

Hyperkinesis (Phase 3)

Hyperplasia (Phase 2)

Hypertension (Phase 1)

Hypotension (Phase 1)

Hypotension, Orthostatic (Phase 1)

Infections (Phase 4)

Inflammatory Bowel Diseases (Phase 2)

Intestinal Diseases (Phase 2)

Keratosis (Phase 1)

Keratosis, Actinic (Phase 1)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Lice Infestations (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 2)

Lymphoma (Phase 1)

Malaria (Phase 2)

Malaria, Falciparum (Phase 1)

Melanoma (Phase 1)

Motor Neuron Disease (Phase 1)

Multiple System Atrophy (Phase 1)

Multiple Trauma (Phase 3)

Mycobacterium Infections (Phase 3)

Mycoses (Phase 4)

Nematode Infections (Phase 4)

Ovarian Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Pharyngitis (Phase 1)

Pneumonia (Phase 4)

Proctitis (Phase 4)

Prostatic Neoplasms (Phase 1)

Pulmonary Fibrosis (Phase 2)

Respiratory Syncytial Virus Infections (Phase 1)

Sclerosis (Phase 1)

Shy-Drager Syndrome (Phase 1)

Streptococcal Infections (Phase 1)

Telangiectasis (Phase 2)

Ulcer (Phase 4)

Uterine Neoplasms (Phase 2)

Virus Diseases (Phase 3)

Wound Infection (Phase 1)

Wounds and Injuries (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 83
# of Trial APIs: 125